Literature DB >> 11206727

Heart rate and plasma cyclic AMP responses to isoproterenol infusion and effect of beta-adrenergic blockade in patients with postural orthostatic tachycardia syndrome.

H Abe1, T Nagatomo, K Kohshi, T Numata, K Kikuchi, S Sonoda, T Mizuki, A Kuroiwa, Y Nakashima.   

Abstract

To clarify the pathophysiological mechanism of postural orthostatic tachycardia syndrome (POTS). the responses of heart rate and the plasma cyclic AMP (cAMP) level to isoproterenol infusion in the supine position were evaluated in 10 POTS patients and 10 age-matched controls. Also, the effect of beta-adrenergic blockade on POTS was assessed using the headup tilt test. The POTS patients consisted of two men and eight women, with a mean age of 19.7 years (range. 15-28 years). An exaggerated increase of both heart rate and the plasma cAMP concentration after isoproterenol infusion at a low dose (1 microg/min) was observed in the POTS patients, but not in control subjects. Seven POTS patients received oral beta-blocker therapy. In five of these, symptoms were abolished and there was a smaller heart rate increase during the head-up tilt test. These data suggest that POTS may be more prevalent in young women and that beta-adrenergic hypersensitivity may play a role in the mechanisms of this syndrome. However, a larger series of patients need to be studied in the future.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11206727     DOI: 10.1097/00005344-200000006-00017

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  6 in total

1.  2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope.

Authors:  Robert S Sheldon; Blair P Grubb; Brian Olshansky; Win-Kuang Shen; Hugh Calkins; Michele Brignole; Satish R Raj; Andrew D Krahn; Carlos A Morillo; Julian M Stewart; Richard Sutton; Paola Sandroni; Karen J Friday; Denise Tessariol Hachul; Mitchell I Cohen; Dennis H Lau; Kenneth A Mayuga; Jeffrey P Moak; Roopinder K Sandhu; Khalil Kanjwal
Journal:  Heart Rhythm       Date:  2015-05-14       Impact factor: 6.343

2.  Low-dose propranolol and exercise capacity in postural tachycardia syndrome: a randomized study.

Authors:  Amy C Arnold; Luis E Okamoto; André Diedrich; Sachin Y Paranjape; Satish R Raj; Italo Biaggioni; Alfredo Gamboa
Journal:  Neurology       Date:  2013-04-24       Impact factor: 9.910

Review 3.  Postural tachycardia syndrome - Diagnosis, physiology, and prognosis.

Authors:  Amy C Arnold; Jessica Ng; Satish R Raj
Journal:  Auton Neurosci       Date:  2018-02-28       Impact factor: 3.145

4.  Diagnostic Value of Diurnal Variability of Orthostatic Heart Rate Increment in Children and Adolescents With POTS.

Authors:  Hong Cai; Shuo Wang; Runmei Zou; Fang Li; Juan Zhang; Yuwen Wang; Yi Xu; Cheng Wang
Journal:  Front Pediatr       Date:  2021-05-13       Impact factor: 3.418

5.  Postural orthostatic tachycardia syndrome (POTS): State of the science and clinical care from a 2019 National Institutes of Health Expert Consensus Meeting - Part 1.

Authors:  Steven Vernino; Kate M Bourne; Lauren E Stiles; Blair P Grubb; Artur Fedorowski; Julian M Stewart; Amy C Arnold; Laura A Pace; Jonas Axelsson; Jeffrey R Boris; Jeffrey P Moak; Brent P Goodman; Kamal R Chémali; Tae H Chung; David S Goldstein; Andre Diedrich; Mitchell G Miglis; Melissa M Cortez; Amanda J Miller; Roy Freeman; Italo Biaggioni; Peter C Rowe; Robert S Sheldon; Cyndya A Shibao; David M Systrom; Glen A Cook; Taylor A Doherty; Hasan I Abdallah; Anil Darbari; Satish R Raj
Journal:  Auton Neurosci       Date:  2021-06-05       Impact factor: 2.355

6.  Adrenergic Autoantibody-Induced Postural Tachycardia Syndrome in Rabbits.

Authors:  Hongliang Li; Gege Zhang; Liping Zhou; Zachary Nuss; Marci Beel; Brendon Hines; Taylor Murphy; Jonathan Liles; Ling Zhang; David C Kem; Xichun Yu
Journal:  J Am Heart Assoc       Date:  2019-09-24       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.